newsfilter
← Latest News
Business Wire·

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Strategic collaboration expands taletrectinib global reach with a leading oncology partner Eisai will receive exclusive development, registration and commercialization rights for taletrectinib for the treatment of